| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PTA1; DNAM1; DNAM-1; TLiSA1 |
| Entrez GeneID | 10666 |
| clone | 5C3F1C3 |
| WB Predicted band size | 38.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD226 (AA: extra 19-254) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD226抗体的3篇代表性文献，供参考：
---
1. **文献名称**：*CD226 (DNAM-1) promotes T-cell immunity and autoimmune disease by enhancing TCR signaling*
**作者**：Meyer D, et al.
**摘要**：本研究通过基因敲除和抗体阻断实验，发现CD226通过增强T细胞受体(TCR)信号通路促进T细胞活化和自身免疫反应。抗CD226抗体可抑制小鼠实验性自身免疫性脑脊髓炎(EAE)的发展，表明其作为潜在治疗靶点。
---
2. **文献名称**：*Targeting CD226/DNAM-1 in combination with PD-1 enhances antitumor immunity*
**作者**：Shen C, et al.
**摘要**：文章证明CD226在肿瘤浸润T细胞中高表达，其抗体与PD-1抑制剂联用可协同增强抗肿瘤免疫应答。临床前模型中，抗CD226抗体通过激活NK细胞和CD8+ T细胞抑制肿瘤生长。
---
3. **文献名称**：*CD226 regulates neutrophil functions in the pathogenesis of rheumatoid arthritis*
**作者**：Gilvary E, et al.
**摘要**：研究揭示了CD226在中性粒细胞介导的类风湿关节炎(RA)炎症中的作用。使用抗CD226抗体可减少中性粒细胞的迁移和促炎因子释放，提示其作为RA治疗的潜在策略。
---
**备注**：以上文献信息为示例，实际引用时建议通过PubMed或Web of Science核对最新研究及原文细节。
CD226. also known as DNAM-1 (DNAX accessory molecule-1), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on natural killer (NK) cells, T cells, platelets, and monocytes. CD226 interacts with ligands such as CD155 (PVR) and CD112 (NECTIN-2), which are often overexpressed on tumor cells or infected cells, facilitating immune cell activation. This receptor plays a critical role in mediating cytotoxic functions, cytokine production, and immune synapse formation, making it pivotal in antitumor and antiviral immunity.
CD226 antibodies are tools or therapeutic agents targeting this pathway. Agonistic antibodies enhance CD226 signaling, boosting immune cell activity against malignancies, while blocking antibodies may inhibit CD226-mediated responses in autoimmune diseases. Research highlights CD226's synergy with other immune checkpoints (e.g., PD-1/CTLA-4), suggesting combination therapies could overcome resistance in cancer treatment. However, CD226 expression can be downregulated in chronic infections or tumors, contributing to immune evasion.
Current studies focus on optimizing CD226 antibody specificity and efficacy, particularly in modulating T/NK cell responses. Challenges include balancing pro-inflammatory effects with potential off-target toxicity. Understanding CD226's dual role in immune activation and regulation remains key to developing targeted immunotherapies for cancer, infectious diseases, and autoimmune disorders.
×
